Golden State Wealth Management LLC Purchases New Shares in Aligos Therapeutics, Inc. (NASDAQ:ALGS)

Golden State Wealth Management LLC acquired a new position in Aligos Therapeutics, Inc. (NASDAQ:ALGS) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 2,674 shares of the company’s stock, valued at approximately $107,000.

Separately, Drive Wealth Management LLC bought a new position in shares of Aligos Therapeutics in the fourth quarter valued at about $916,000. Institutional investors and hedge funds own 60.43% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a “buy” rating and set a $75.00 price objective on shares of Aligos Therapeutics in a report on Thursday, November 7th.

Aligos Therapeutics Price Performance

Shares of Aligos Therapeutics stock opened at $27.53 on Monday. The firm has a 50 day simple moving average of $33.10 and a 200 day simple moving average of $19.68. Aligos Therapeutics, Inc. has a fifty-two week low of $6.76 and a fifty-two week high of $46.80. The firm has a market cap of $98.83 million, a P/E ratio of -2.07 and a beta of 2.45.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).